DDInter1544 DDInter32
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test . Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim .
Afatinib {u} (Compound) resembles {v} (Compound) Gefitinib
Afatinib {u} (Compound) binds {v} (Gene) ABCB1
Afatinib {u} (Compound) upregulates {v} (Gene) MTHFD2
Afatinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Afatinib {u} (Compound) downregulates {v} (Gene) IGFBP2
Afatinib {u} (Compound) causes {v} (Side Effect) Diarrhoea
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fosphenytoin
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Afatinib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Afatinib {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) ERBB2
Afatinib (Compound) resembles Gefitinib (Compound)
Afatinib (Compound) binds ABCB1 (Gene)
Afatinib (Compound) upregulates MTHFD2 (Gene)
Afatinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Afatinib (Compound) downregulates IGFBP2 (Gene)
Afatinib (Compound) causes Diarrhoea (Side Effect)
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Afatinib may lead to a major life threatening interaction when taken with Lomitapide
Afatinib (Compound) binds ERBB2 (Gene) and Afatinib (Compound) downregulates ERBB2 (Gene)